Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138772 | Leukemia Research | 2006 | 7 Pages |
Abstract
We report the establishment and characterization, including HLA-typing, immunophenotypic and molecular cytogenetic analysis, of a novel EBV-negative cell line (BLUE-1) derived from adult relapsed sporadic Burkitt lymphoma. BLUE-1 carries the pathognomonic t(8;14)(q24;q32) effecting MYC/IgHJ fusion and a novel t(6;20)(q15;q11.2) originally present in the patient, analysis of which may facilitate identification of gene target(s) of recurrent 6q rearrangements in B-cell neoplasia. Our findings are discussed in light of the current understanding of endemic and sporadic Burkitt lymphoma. BLUE-1 grows well in culture and should be a useful lymphoma research tool.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Thomas Burmeister, Roderick A.F. MacLeod, Richard Reinhardt, Veit Mansmann, Christoph Loddenkemper, Olga Marinets, Hans G. Drexler, Eckhard Thiel, Igor Wolfgang Blau,